Marketing

Vet drugmakers get Warning Letters too

Regulatory Focus reports that the regulator has issued a Warning Letter to AB Science for marketing its canine tumor drug Kinavet for unapproved, off-label uses.

Takeda walks away from Omontys

The drugmaker is pulling its US marketing application for the anemia drug.

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

By

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Court reverses Risperdal decision

The Arkansas Supreme Court's decision puts $1.2 billion back into J&J's coffers.

DOJ may cost Aegerion patients

The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.

Roche silences Herceptin comparison

A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.

Weight-loss drugs plateau and expand

Weight-loss drugs plateau and expand

By

Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.

Amped-up Victoza marketing hurts GLP-1 rivals

By

Novo redoubled its Victoza marketing efforts after a recent setback, and that's made things tougher for GLP-1 rivals Bristol-Myers Squibb and AstraZeneca.

J&J painkiller probe expands scrutiny of industry marketing

By

HHS is looking into how J&J marketed opioid painkiller Nucynta, adding to the firm's list of investigations and those of the industry as a whole.

Genetic testing firm airs TV spot as part of $5M ad buy

Genetic testing firm airs TV spot as part of $5M ad buy

By

23andMe aired its first TV ad Monday, in a bid to build the audience for DNA sequencing.

Publicis Omnicom merger puts healthcare clients under one roof

Publicis Omnicom merger puts healthcare clients under one roof

By

Over the weekend, Publicis Omnicom vaulted past WPP to become the world's biggest ad holding company. The task now falls on its co-CEOs to sort out any conflicts and prevent defections.

Obesity marketing to stay same, despite new AMA designation

Obesity marketing to stay same, despite new AMA designation

By

Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.

Victoza in its crosshairs, Lilly primes for marketing duel

By

Eli Lilly's GLP-1 drug is still in Phase III, but recently released data suggest it could be a formidable competitor to the already marketed GLP-1 drugs, including Novo's market-leading Victoza.

Novartis: lawsuits, layoffs and, by the way, earnings

By

It was an all-in-one news day for the drug maker which, by the way, saw sales rise 2% for the first quarter, compared to the same period last year.

Success in emerging markets hinges on broad network

By

Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.

Social media guru Gwee joins Chandler Chicco

Social media guru Gwee joins Chandler Chicco

By

Gwee, who pioneered pharma social media at Vertex before moving onto the agency side, is tasked with integrating digital and social strategies across the marketing and PR network's 14 agencies.

Why SGLT-2s may put some spring into pharma spending

Why SGLT-2s may put some spring into pharma spending

Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.

Note to sales: don't panic when reading these numbers

By

At first blush, Accenture's survey of pharma execs looks like more bad news for sales forces, but the firm tells MM&M that the sales overhauls are about more than reducing headcounts.

IMS Health gobbles up SaaS firm Appature

By

IMS Health has acquired Seattle-based software-as-a-service (SaaS) company Appature, the firms are expected to announce today.

Business briefs: Lundbeck, FDA, Tower Watson and National Business Group Study, Merck

Lundbeck and Otsuka deepen their Abilify co-promotion partnership; study finds FDA clinical trial rule isn't sticking; another study confirms that employees are paying more for health insurance as employers pay less; Merck appoints new R&D chief

Gift study shows med students still being comped

By

Gift bans or no, students still connect with drug companies, a study has found.

Docs to pharma marketers: you're not getting it

Docs to pharma marketers: you're not getting it

By

An ePharma Summit panel of physicians takes the sheen off new marketing initiatives by telling pharmas they find them useless.

Business briefs: Gilead, Shire, The Medicines Co., HHS

HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.

Researchers find schools minting pitch-resistant docs

By

A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors' recommendations.

Santarus loads up on sales reps

By

The company is beefing up its marketing staff, using an iPad-equipped mix of in-house and contracted talent.

Orexigen rethinks clinical trial recruitment

By

Orexigen slashed its clinical trial recruitment period by 14 months using marketing tactics associated with retail.

Study says color and shape linked to Rx adherence

By

A study on the effect that a medication's color and shape have on adherence gives short shrift to the marketing component that urges patients not to take medications that don't conform to doctors' orders

Transcept, Purdue plan DTC effort to revive sleep-drug launch

By

Facing lower-than-expected demand, Purdue and Transcept are broadening the commercial strategy for Intermezzo to include DTC and a larger selling force.

Mylan expands Epi-Pen strategy

Mylan expands Epi-Pen strategy

By

Emmy-winner Julie Bowen is part of the effort to spread allergy education and awareness in schools.

Search doubles as health narrative, Google finds

By

Google's latest data shows that the doctor-patient information divide isn't so much a divide as two parts of the same conversation.

Email Newsletters